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Abstract
BRCA1-associated protein 1 (BAP1) is a nuclear deubiquitinating enzyme that is associated with multiprotein
complexes that regulate key cellular pathways, including cell cycle, cellular differentiation, cell death, and the DNA
damage response. In this study, we found that the reduced expression of BAP1 pro6motes the survival of
neuroblastoma cells, and restoring the levels of BAP1 in these cells facilitated a delay in S and G2/M phase of the cell
cycle, as well as cell apoptosis. The mechanism that BAP1 induces cell death is mediated via an interaction with 14-3-3
protein. The association between BAP1 and 14-3-3 protein releases the apoptotic inducer protein Bax from 14-3-3 and
promotes cell death through the intrinsic apoptosis pathway. Xenograft studies conﬁrmed that the expression of BAP1
reduces tumor growth and progression in vivo by lowering the levels of pro-survival factors such as Bcl-2, which in
turn diminish the survival potential of the tumor cells. Patient data analyses conﬁrmed the ﬁnding that the high-BAP1
mRNA expression correlates with a better clinical outcome. In summary, our study uncovers a new mechanism for
BAP1 in the regulation of cell apoptosis in neuroblastoma cells.
Introduction
Neuroblastoma originates from the sympathetic ner-
vous system and is composed of undifferentiated and
poorly differentiated neuroblasts arising from the differ-
ent stages of the sympathoadrenal lineage of neural crest
origin1. The patient age, N-Myc ampliﬁcation, deletion of
the chromosome, and metastatic spread are important
factors with regard to treatment decision and patient
prognosis. Although, N-Myc has important prognostic
value, ampliﬁcation is only observed in about 25% of
neuroblastoma cases and other factors contributing to
high-risk neuroblastoma are not known2. Surgery, radio-
therapy, and intensive induction chemotherapy with
autologous stem cell transplantation are commonly used
as treatment therapy for neuroblastoma patients. In
addition, terminal differentiation therapy and immu-
notherapy is used as a current standard therapy for high-
risk neuroblastomas in order to eliminate residual tumor
cells that are resistant after chemotherapy and stem cell
transplantation3–5.
Tumorigenesis in neuroblastoma can be caused by the
upregulation of cell survival signaling and the lack of
cellular apoptosis. Therefore, understanding the
mechanism that leads to cell survival pathways can pro-
vide avenues for the development of novel therapeutics.
The hallmark of apoptosis is the activation of caspases
that coordinate cleavage of substrates leading to cell
death. Generally, apoptosis is divided into the extrinsic
and intrinsic pathway. The extrinsic pathway is mediated
via cell surface death receptors; whereas, the intrinsic
pathway is mediated via the mitochondrial6–9. DNA-
damaged cells are eliminated by the intrinsic pathway in
which the Bcl-2 family of proteins plays a critical role9.
This family is divided into anti-apoptotic proteins
(including Bcl-2, Bcl-XL, and Mcl-1), and pro-apoptotic
proteins, which is further divided into multi-domain
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proteins, such as Bax, Bak, and BH3-only proteins,
including Bad, Bim, and HRK/DP5. Tumor cells often
increase the expression of anti-apoptotic Bcl-2 members
to avoid cancer cells undergoing apoptosis. Indeed, in a
large subset of neuroblastoma patients, an elevated level
of Bcl-2 has been detected10,11. Besides regulating cancer
cell survival, chemotherapy-induced apoptosis is blocked
in neuroblastoma through the involvement of the Bcl-2
protein family12.
BRCA1-associated protein 1 (BAP1) is a deubiquiti-
nating enzyme that was discovered through its interaction
with the RING ﬁnger domain of tumor suppressor protein
BRCA113,14. BAP1 is a tumor suppressor gene deleted or
mutated in various human cancer types, including breast,
lung, renal cell carcinoma, metastatic uveal melanomas,
and malignant pleural mesotheliomas13,15–18. In mice, the
disruption of BAP1 leads to the development of myeloid
neoplasia19; whereas, the expression of BAP1 suppresses
the growth of non-small cell lung carcinoma cells in nude
mice15. Another function of BAP1 is to prevent abnormal
mitotic spindle formation and genome instability via the
deubiquitination of α-tubulin in human breast cancer
cells20. BAP1 can also interact with several proteins
associated with chromatin and transcription regulation,
such as sex combs-like ASXL1 and ASXL2, forkhead
transcription factors FOXK1 and FOXK2, lysine-speciﬁc
demethylase 1B (KDM1B), O-linked N-acetylglucosamine
transferase (OGT), and host cell factor 1 (HCF-1)21–23.
Previous studies have shown that BAP1 has a role in cell
cycle regulation and cell proliferation15,19,22,24,25. Further,
BAP1 can regulate the cell cycle by inﬂuencing the
expression of E2F1 target genes in uveal melanoma cells26.
The regulation of DNA damage response by BAP1 is
mediated via rapid poly(ADP-ribose)-dependent recruit-
ment of the polycomb repressive deubiquitination (PR-
DUB) complex to sites of DNA damage27,28. Phosphor-
ylation of BAP1 at S592 is an important regulatory
mechanism to dissociate BAP1 from chromatin and
regulate-speciﬁc genes during DNA replication and
repair29.
In this study, we investigated the role of BAP1 as a
tumor suppressor gene in neuroblastoma based on the
3p-chromosomal location of BAP1 and that alteration in
chromosome arms 3p is a common event in neuro-
blastoma. It was found that the pro-apoptotic function of
BAP1 is mediated via binding to 14-3-3 protein, which
further facilitated cell death signaling in neuroblastoma.
Materials and methods
Cell culture
The human neuroblastoma cell lines were cultured for
5 days at 37 °C and 5% CO2 as follows: IMR32 (ATCC,
CCL-127), SK-N-SH-RA30,31, SK-N-FI (ATCC, CRL-
2142), SK-N-SH (ATCC, HTB-11), and SK-N-DZ (ATCC,
CRL-2149) cells were cultured in RPMI 1640 Medium
(HyClone, Thermo Scientiﬁc, USA), supplemented with
10% FBS (Sigma-Aldrich, Sweden), and 0.1% penicillin/
streptomycin (Gibco, Life Technologies, UK). SK-N-Be2c
cells (ATCC, CRL-2271) were cultured in MEM
(HyClone, Thermo Scientiﬁc, USA) supplemented with
10% FBS (Sigma-Aldrich) and 0.1% penicillin/streptomy-
cin (Gibco).
Animal model
SK-N-Be2c cells (5.0 × 106 cells in 0.1 mL PBS) stably
expressing BAP1 or control expression plasmid (10 in
each group) and SK-N-FI cells were subcutaneously
injected into the dorsal left or right ﬂank of 4-week-old
female NMRI-nu/NMRI-Foxn1nu/nu (Janvier Labs). The
animals were maintained under speciﬁc pathogen-free
(SPF) conditions. All experimental procedures were
approved by the Malmo and Lund Animal Ethics Com-
mittee with the ethical number M129-15. The tumor
growth was followed by measuring the volume every ﬁfth
day. The subcutaneous tumors were collected, weighed,
and chosen for further study.
Transient transfection
Transient transfection assays were carried out in six-
well plates at 60% conﬂuence, using PolyFect Transfection
Reagent (Qiagen) or Lipofectamine®2000 Reagent (Invi-
trogen, life technologies) in accordance with the manu-
facturer’s recommendations. Twenty-four hours prior to
transfection, cells were seeded in medium containing 10%
FBS. Cells were incubated at 37 °C and 5% CO2 for 24–48
h. The medium was removed and the cells washed with
PBS, after which fresh serum-containing medium was
added to the cells. DNA, 1.5–4.0 µg, was mixed with an
appropriate volume of OptiMEM (Sigma), followed by the
addition of 10–25 µl PolyFect transfection reagent. The
samples were incubated at room temperature for 10min,
in order to allow the complex formation to be completed,
prior to being transferred to the cells. Cells were subse-
quently incubated for 24–48 h, collected and used for
further analyses.
Transient transfection of siRNA (10 µM) was performed
in six-well plates at 60% conﬂuence, using Lipofectamine®
RNAiMAX Reagent (Invitrogen, life technologies) fol-
lowing the manufacturer’s instructions. Forty-eight hours
post transfection, cells were collected and used for further




The non-transfected SK-N-RA cells in six-well plates
were treated for 24 h with BV02 (SML0140, Sigma-
Aldrich) at different concentrations (5, 20, and 100 µM).
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The percentages of apoptotic cells were determined using
the Burkers chamber.
Cell lysis and subcellular fractionation
Cells were grown on 10 cm plates to 80% conﬂuence,
collected in PBS, and lysed in buffer comprising 1M Tris-
HCl (pH 7.6), 5M NaCl, 0.5M EDTA, 1% Triton X-100,
and Complete® protease inhibitor cocktail (Roche, Ger-
many). The extraction of protein from tumor tissue was
prepared after samples were homogenized and sonicated
in cold RIPA buffer (50 mM Tris-HCl, pH 7.4, 150mM
NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0%
sodium deoxycholate) freshly supplemented with protease
inhibitor cocktail (Roche, Germany). After centrifugation
at 10,000×g for 15 min at 4 °C, the protein in the super-
natant was measured using the Protein concentration and
was assessed using the Bradford method and sample
concentrations were adjusted accordingly. Lysates were
boiled for 5 minutes at 100 °C with a 2× sample buffer,
containing 1 mM dithiothreitol (DTT).
For cell fractionation, cells were ﬁrst resuspended in ice-
cold buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 1.5
mM MgCl2, 0.34M sucrose, 10% glycerol, 1 mM DTT,
complete protease inhibitors EDTA-free (Roche, Ger-
many) and 0.1 mM phenylmethylsulfonyl ﬂuoride), 0.1%
Triton X-100 was added followed by incubation for 10
min on ice, and centrifuged at 4 °C for 5 min at 1300×g.
The supernatant containing cytosolic fraction was
removed and the pellet was enriched in chromatin and
washed once in buffer A before re-suspension in protein
sample buffer (2% SDS, 312.5 mM Tris, pH 6.8, 5% gly-
cerol, 0.003% BFB, and 50 mM DTT) and boiled in sample
buffer for 10min and analyzed by western blotting using
anti-tubulin (Sigma-Aldrich, Sweden) and anti-LaminB
(Thermo Scientiﬁc, USA) as molecular markers for the
cytosolic and nuclear fractions, respectively.
Cell cycle synchronization
Cells were synchronized in G0/G1 or G2/M phase
either by serum starvation for 48 h or nocodazole treat-
ment for 18 h (100 ng/ml, sigma) respectively. The syn-
chronized cells were released from their respective
arrested phase by the addition of 10% serum containing
RPMI (HyClone, Thermo scientiﬁc, USA), and samples
were taken at various times. The cells were ﬁxed by
dripping ice-cold 70% ethanol while vortexing the cells
vigorously and stored for 12–24 h at −20 °C. Ethanol-
suspended cells were centrifuged and the ethanol carefully
decanted. The cells were washed once with PBS and then
resuspended with NucleoCounter Solution 3 (1 μg/ml
4′,6-diamidino-2-phenylindole, 0.1% Triton X-100 in
PBS), followed by incubation for 5 min at 37 °C. Samples
of 10 μl volume were loaded into a slide chamber (NC-
slide A8), and the DNA fragmentation protocol was used
according to the manufacturer’s instructions (Chemo-
Metec). To assess the cell cycle proﬁle following noco-
dazole synchronization, ethanol-ﬁxed cells were washed
twice with PBS, resuspended in propidium iodide (PI)
staining solution (20 μg/ml PI, 200 μg/ml Rnase A in PBS
containing 0.1% Triton X-100), and incubated at 37 °C for
30min. For each condition, 10,000 cells were analyzed by
a ﬂow cytometer (BD FACS Verse™) and the cell cycle
proﬁle was analyzed using the FlowJo v10 software.
Western blot analysis
Western blotting was carried out, following standard
protocol. The membrane was incubated with primary
antibody in 5% BSA followed incubation with corre-
sponding horseradish peroxidase (HRP)–conjugated sec-
ondary antibody (DAKO, Denmark) for 1 h at RT. Bands
were detected using immunochemical detection accord-
ing to the manufacturer’s instruction (Santa Cruz, USA).
For the chemiluminescent reaction, Supersignal Substrate
(Thermo Scientiﬁc) was used according to manufacturer’s
instructions. Chemiluminescence was detected with an
LAS-1000 charge-coupled device camera (Fujiﬁlm) and
images were processed using the ImageJ software.
Quantitative PCR
The cells were rinsed in cold PBS and total RNA
extracted using the Perfect Pure RNA tissue kit (5 PRIME,
Germany) according to manufacturer’s instruction. The
purity of RNA was analyzed and quantiﬁed by a Nano-
Drop spectrophotometer (Saveen Werner, Sweden) and
used for cDNA synthesis according to the manufacturer’s
instruction (QPCR cDNA synthesis kit, Stratagene, USA).
PCR runs were performed in the QuantStudioTM 7 Flex
System using SYBR®Green Reagent (Applied Biosystems),
with the following program; 2 min 50 °C, 10 min in 95 °C
followed by 40 three-step cycles consisting of 95 °C for 20










Retrovirus production and transduction
Retroviral vector alone or vector encoding wild-type
FLAG and HA-tagged BAP1 (plasmid 22539) containing a
puromycin resistance gene for selection of stably trans-
duced cells were obtained from Add gene. Retrovirus
production was performed by Research engineer, Vector
Unit at Lund University, Sweden. Cells were seeded in six-
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well plates with 40% conﬂuency in RPMI medium
(HyClone, Thermo-scientiﬁc, USA) supplemented with
10% FBS, 2 mM L-glutamine, 100 units/mL penicillin and
100 µg/mL streptomycin (Sigma-Aldrich, Sweden). Next
day, the medium was changed with 1ml medium con-
taining hexadimethrine bromide (Sigma-Aldrich, Sweden;
ﬁnal concentration 8mg/ml) to each well. A total of 10 µl
of retroviral particles was added to appropriate wells and
cells were incubated 24 h at 37 °C in a humidiﬁed incu-
bator in an atmosphere of 5–7% CO2. The medium was
changed with 1 ml RPMI containing puromycin (Sigma-
Aldrich, Sweden). The transduction efﬁciency was initially
evaluated using western blot and Immunoﬂuorescence
staining.
Apoptosis and cell proliferation
Cells were grown on six-well plates, collected at 24 or
48 h post transfection, and counted using the Burkers
chamber, or Countess® Automated Cell Counter (Invi-
trogen). For apoptosis analyses, the cells were ﬁxed in PFA
on coverslips, and stained with a Vindelöv solution,
containing propidium iodide. After washing, the cover-
slips were mounted onto glass slides and examined by
ﬂuorescence microscopy. Cells were scored for apoptosis,
based on nuclear morphology. Apoptosis was furthermore
evaluated, using NucleoCounter NC-3000 (Chemometec),
in conformity with the DNA fragmentation assay. Brieﬂy,
transfected and non-transfected cells (controls) were
grown on 6-well plates. The cells were collected by
trypsinization and pooled with the cells ﬂoating in the
medium. After a short centrifugation, the supernatant was
removed and the precipitated cells were washed once with
PBS. After a second centrifugation, the cells were resus-
pended in a small volume of PBS, and the single-cell
suspensions were added to 70% ethanol for ﬁxation. The
samples were vortexed and stored for 12–24 h at −20 °C.
The ethanol-suspended cells were centrifuged and the
ethanol carefully decanted. Cells were washed once with
PBS and then resuspended with NucleoCounter Solution
3 (1 µg/ml DAPI, 0.1% Triton X-100 in PBS), followed by
incubation for 5 min at 37 °C. The samples of 10 µl
volume were loaded into a slide chamber (NC-slide A8),
and the DNA Fragmentation protocol was employed
according to manufacturer’s instructions (Chemometec).
EdU incorporation: A thymidine analog, 5-ethynyl-2′-
deoxyuridine (EdU), incorporation was used to measure
cell proliferation using Click-iT® EdU Alexa Flour 488 cell
proliferation assay kit (Thermo Fisher Scientiﬁc). Brieﬂy,
BAP1-low and BAP1-overexpressing SK-N-SH cells were
seeded in a six-well plate (250 × 103 cells/well) in DMEM
with 10% FBS containing EdU (5 µM/well) and incubated
at 37 °C. After 24, 48, and 72 h, the cells were collected,
washed twice in PBS containing 1% BSA and click-iT
reaction was performed on ﬁxed cells before FACS
analysis was carried out to determine the fraction of
proliferating cells. To deﬁne EdU labeled cell fractions
(Click-iT EdU Alexa Flour 488 positive), EdU-unlabeled
SK-N-SH cells were used as a negative control after
simultaneously stained with click-iT reaction solution.
For each condition, 20,000 events were acquired by a ﬂow
cytometer (BD FACS Verse™) and the percentage indi-
cated in the bar graph was analyzed using FlowJo
v10 software. The results are the mean of two indepen-
dent experiments.
Annexin V-phycoerythrin staining and ﬂuorescence-
activated cell sorting analysis
Cells were stained using Annexin V-phycoerythrin (PE)
apoptosis detection kit (BD Pharmingen) according to the
manufacturer’s recommendations. Brieﬂy, the ﬂoating
cells in the medium together with the respective adhered
cells were collected and washed twice with ice-cold PBS
before suspended in 100 μl binding buffer (1 × 106/ml).
Next, Annexin V-PE (5 µl) and 7-AAD (5 µl) were added
and the mixture was incubated for 15min in the dark.
Finally, 400 µl binding buffer was added to the cells and
analyzed using a ﬂow cytometer (BD FACS Verse™). The
data analysis was performed using FlowJo v10 software.
Measurement of mitochondrial membrane potential
The mitochondrial membrane potential (ΔΨm) was
evaluated by ﬂow cytometric analysis with JC-1 staining.
Stably transduced neuroblastoma cells both with empty
vector (control) and BAP1 were collected after trypsini-
zation. For arsenic induction, cells were seeded in 100mm
Petri dish (5 × 105 cells) for 48 h, and then treated with
arsenic trioxide (6 µM) and collected after 24 h. The cells
resuspended in PBS (1 × 106) following washing steps
were incubated with 5 µM JC-1 at 37 °C, 5% CO2, for 30
min in the dark. For each condition, 10,000 events were
acquired by a ﬂow cytometer (BD FACS Verse™) and the
percentage indicated in the dot plot was analyzed using
FlowJo v10 software.
LC–MS/MS analysis
MS analyses were carried out on an Orbitrap Fusion
Tribrid MS system (Thermo Scientiﬁc) equipped with a
Proxeon Easy-nLC 1000 (Thermo Fisher). Injected pep-
tides were trapped on an Acclaim PepMap C18 column
(3 µm particle size, 75 µm inner diameter × 20mm
length). After trapping, gradient elution of peptides was
performed on an Acclaim PepMap C18 100 Å 3 μm, 150
mm, 75 μm). The outlet of the analytical column was
coupled directly to the mass spectrometer using a Prox-
eon nanospray source. The mobile phases for LC
separation were 0.1% (v/v) formic acid in LC–MS grade
water (solvent A) and 0.1% (v/v) formic acid in acetoni-
trile (solvent B). Peptides were ﬁrst loaded with a constant
Sime et al. Cell Death and Disease  (2018) 9:458 Page 4 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
pressure mode with a ﬂowrate of solvent A onto the
trapping column. Subsequently, peptides were eluted via
the analytical column at a constant ﬂow of 300 nl/min.
During the elution step, the percentage of solvent B
increased in a linear fashion from 5 to 10% in 2 min, then
increased to 25% in 85min and ﬁnally to 60% in a further
20min. The peptides were introduced into the mass
spectrometer via a Stainless steel emitter 40 mm (Thermo
Fisher) and a spray voltage of 2.0 kV was applied. The
capillary temperature was set at 275 °C. Data acquisition
was carried out using a data-dependent top N method
with cycle time of 2 s. The master scan was performed in
the Orbitrap in the range of 380–1580m/z at a resolution
of 60,000 FWHM. The ﬁlling time was set at maximum of
50ms with limitation of 4 × 105 ions. Ion trap CID-MS2
was acquired using parallel mode, ﬁlling time 50ms with
limitation of 1.5 × 104 ions, a precursor ion isolation
width of 0.7 m/z and resolution of 30,000 FWHM. Nor-
malized collision energy was set to 35%. Only multiply
charged (2+ to 4+) precursor ions were selected for MS2.
The dynamic exclusion list was set to 30 s and a relative
mass window of 5 p.p.m.
Pull-down assay
Ni-NTA pull-down assay: SK-N-RA cells were trans-
fected with His6-ubiquitin and/or BAP1 expressing plas-
mids. Cells were lysed after 24 h in 8M UREA, 100mM
Na2HPO4/NaH2PO4; 10 mM Tris, pH 8.0, 10 mM imi-
dazole and 5mM DTT, and lysates (1 mg) were incubated
with 40 μl Ni-NTA Superﬂow (Qiagen) overnight at room
temperature. The resin was washed three times with lysis
buffer, once with 8M UREA, 100 mM Na2HPO4/
NaH2PO4; 10 mM Tris, pH 6.3; 10 mM imidazole; 5 mM
DTT and once more with lysis buffer before eluting
proteins with lysis buffer containing 200mM imidazole.
Isolated proteins were subjected to immunoblotting using
antibodies against ubiquitin at 1:1000 (SC-8017, Santa
Cruz) or pan-14-3-3 at 1:500 (SC-629, Santa Cruz).
GST pull-down assay: Co-transfected cells were lysed in
1% NP-40 buffer (20 mM Tris (pH 8.0), 137mM NaCl, 5%
glycerol, 1% nonident P-40, Protease Inhibitor (Sigma,
P8340, USA) and phosphatase inhibitor (Sigma, P5726,
USA) and centrifuged for 10 min at 4 °C. Aliquots were
taken for input control and the remaining lysate were
incubated with pre-washed (with lysis buffer) glutathione-
conjugated sepharose beads (GE, 17075605, Sweden) for
3 h at 4 °C. After washing three times with 1% NP-40
buffer, the beads were resuspended in sample buffer (Bio-
Rad, 1610737, USA) and boiled at 95 °C for 5 min. Then
the eluted samples and whole-cell lysate were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) and analyzed by western blot with the
anti-Flag antibody at 1:3000 (Sigma, A8592, USA), anti-
GST antibody at 1:3000 (Sigma, A7340, USA) and anti-β-
Actin antibody at 1:5000 (Sigma, A5441, USA).
Time-resolved ﬂuorescence resonance energy transfer (TR-
FRET) assay
The TR-FRET assay was carried out with puriﬁed pro-
teins in 384-well black solid bottom plates (Corning, 3573,
USA). His-BAP1 protein (Boston Biochem, E-345, USA),
control GST protein (Abcam, ab70456, USA) and puriﬁed
GST-14-3-3 proteins were mixed in a total volume of 30
µl FRET buffer (20 mM Tris (pH 7.0), 50 mM NaCl, 0.01%
NP-40). Anti-GST-Terbium antibody (Cisbio,
61GSTTLB, USA) and anti-His-D2 antibody (Cisbio,
61HISDLA, USA) were added to each well at the ﬁnal
dilution of 1:1000 and 1:500, respectively. The FRET
signals were detected using Envision spectrophotometer
(Laser excitation at 337 nm, emission for the donor at 620
nm and emission for acceptor at 665 nm). The data were
presented as the ratio of (counts at 665/counts at 620
nm) × 104 with standard deviation calculated from tripli-
cate samples.
Immunoﬂuorescence and confocal microscopy
Cells were cultured on coverslips in six-well plates for
24 h and then ﬁxed in paraformaldehyde (PFA) (4% for 15
min). Next, the cells were permeabilized with 0.3% Triton
X-100 solution, after which they were blocked with 1%
BSA and 5% goat serum for 30min to prevent non-
speciﬁc antibody binding, and subsequently incubated for
1 h with primary antibodies against BAP1 (Clone C-4; sc-
28383, Santa Cruz, USA), α-tubulin (Sigma-Aldrich,
Sweden), and FLAG (Sigma-Aldrich, Sweden). After
washing coverslips, ﬂuorescent antibodies (Alexa 488 goat
anti-mouse or Alexa 546 goat anti-rabbit (Invitrogen,
USA)) were applied, then the coverslips were washed and
mounted in VECTASHIELD® with diamidino-2-
phenylindole (DAPI) (Vector Laboratories). The images
were obtained using a Zeiss LSM710 confocal microscope.
RT2 proﬁler PCR array analysis
The apoptosis pathway-focused gene expression proﬁl-
ing was performed using a 384-well human RT2 Proﬁler
PCR Array PAHS-012ZE (Qiagen). Following the total
RNA extraction, cDNA was synthesized from SK-N-RA
cells transiently transfected with an empty vector used as
control (GFP) and full-length BAP1 based on the manu-
facturer’s instructions. In this array, 84 different genes
involved in programmed cell death were analyzed based
on SYBR Green real-time PCR using the QuantStudio™ 7
Flex (Applied Biosystems™). Normalization was per-
formed using the ﬁve different housekeeping genes
included in the array and the fold-change was calculated
using the RT2 Proﬁler PCR Array Data Analysis.
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Gene expression data for survival
BAP1 and Bax normalized gene expression array data
(Affymetrix HG-U133A [GPL96] and HG-U133B
[GPL97] platforms; GSE3446) of 102 neuroblastoma
patients were downloaded from the website R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl). To
test the association of gene expression levels with relapse-
free survival, individual gene expression proﬁles were
dichotomized by median split into “high” or “low”
expression groups, and Kaplan–Meier survival curves
were plotted for each group.
Statistical analyses
Statistical analyses were performed using SigmaPlot
software. The results are expressed as mean ± s.e.m. or as
a percent. P-values <0.05 were deemed statistically sig-
niﬁcant. Statistical comparisons were assessed by
ANOVA or by Student’s t-test (p < 0.05).
Results
Reduced levels of BAP1 in neuroblastoma cells
In order to investigate whether BAP1 expression is
altered in neuroblastoma, we studied the levels of BAP1
expression in different neuroblastoma cell lines. It was
found that BAP1 was signiﬁcantly downregulated at the
mRNA and protein levels in the SK-N-BE2c, SK-N-SH,
SK-N-RA, KcN-69n, and SH-S454 cells compared to
IMR32 and SK-N-F1 cells (Fig. 1a, b and Supplementary
Fig. 1). To investigate the role of BAP1 in neuroblastoma,
SK-N-SH, SK-N-RA, and SK-N-BE2c cells were virally
infected with full-length BAP1 tagged with HA and FLAG
(Supplementary Fig. 2). Monitoring cell morphology of
neuroblastoma cells expressing full-length BAP1 showed
that these cells but not the cells expressing a control
plasmid or the cells expressing a catalytically inactive
mutant of BAP1 (BAP1-C91A) facilitated neurite out-
growth 72–96 h post transfection (Fig. 1c, d and Supple-
mentary Fig. 3). Neurite outgrowth can indicate the non-
proliferative stage of the cells and this can interfere with
the survival of neuroblastoma cells32. To determine
whether BAP1 can affect cell growth, we analyzed the
proliferation rate of BAP1, BAP1-C91A, and GFP control
(Ctrl.) expression plasmid lentivirus infected cells. Rescue
expression of BAP1, but not BAP1-C91A in two neuro-
blastoma cells lines reduced the proliferation rate at 48
and 72 h, compared with control cells (Fig. 1e and sup-
plementary Fig. 4). The effect of BAP1 overexpression in
altering cell cycle progression was demonstrated in non-
synchronized SK-N-Be2c cells where the frequency of
cells in the S, G2/M, and subG1 phases were higher
compared to the control or BAP1-C91A expressing cells
(Fig. 1f and Supplementary Fig. 5). To conﬁrm this result,
we synchronized the cells in G2/M phase by treating the
cells with nocodazole (Fig. 1g, left panels). The release of
synchronization after 48 h showed an accumulation of
cells in the S, G2/M, and subG1 phases in BAP1 expres-
sing cells compared to control cells (Fig. 1g, right panels).
BAP1 promotes cell death in neuroblastoma cells
Next, we investigated whether the accumulation of
BAP1 expressing cells in subG1indicates cell death. The
percentage of Annexin V positive cells (Fig. 2a) or cells
having fragmented DNA (Fig. 2b) were signiﬁcantly
higher in the BAP1 expressing cells compared to BAP1-
C91A or control cells (Fig. 2b). PI staining also displayed a
higher number of BAP1 expressing cells undergoing cell
death compared to BAP1-C91A or control cells (Fig. 2c).
In cell cycle synchronized neuroblastoma cells, we mon-
itored the commitment of BAP1 expressing cells to
apoptosis after release. Poly (ADP-ribose) polymerase
(PARP) cleavage was detected within 15–22 h post release
in BAP1 but not in control expressing cells (Fig. 2d and
Supplementary Fig. 6). Investigating the mitochondrial
membrane potential (ΔΨm) in non-treated or arsenic-
treated cells showed an elevated number of JC-1 dye
positive cells (Fig. 2e, middle and right panels) and an
intense release of Mito Tracker into the cytosol (Supple-
mentary Fig. 7) in BAP1 expressing cells compared to
control cells. These results suggest that BAP1 interfere
with the intrinsic apoptosis pathway in neuroblastoma
cells. Furthermore, transient transfection of neuro-
blastoma with increasing concentrations of the BAP1-
cDNA showed a direct correlation between levels of BAP1
expression and cell death (Fig. 2f and Supplementary
Fig. 8). The comparison of growth rate between neuro-
blastoma cells revealed that low-expressing BAP1 cells,
SK-N-DZ cells (Supplementary Fig. 9A) showed an ele-
vated proliferation rate and cell cycle progression, as well
as reduced cell death compared with BAP1 expressing SK-
N-F1 cells (Supplementary Fig. 9B-D). In addition, low-
expressing BAP1 cells, SK-N-Be2c cells develop tumors
(90% of animals) in xenograft experiments compared to
BAP1 expressing SK-N-FI cells (10% of animals) (Sup-
plementary Fig. 9E). Further, downregulation of BAP1 in
SK-N-FI cells by using small interfering RNA (siRNA)
(Supplementary Fig. 10A) enhanced cell survival com-
pared to siRNA treated control cells (Supplementary
Fig. 10B-C). Treatment of BAP1-overexpressing cells with
siRNA oligos against BAP1 reversed this effect and pro-
moted survival of the cells (Fig. 2g), as well as reduced the
subG1 population of the cells (Fig. 2h).
To identify the global BAP-mediated pro- and anti-
apoptotic genes in neuroblastoma cells, we tested the
expression proﬁles of 84 well-known genes involved in
apoptosis and survival pathways. While few genes
encoding pro-apoptotic proteins (HRK, CD70) were
upregulated, other genes encoding anti-apoptotic proteins
(BCL2L1, XIAP, BCL2L10, and BFAR) were
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downregulated in BAP1 expressing cells compared to the
control cells (Fig. 2i). This result was conﬁrmed by
showing that the transient overexpression of BAP1
downregulates the total levels of Bcl-2, 24–48 h post
transfection (Fig. 2j).
BAP1 binding to 14-3-3 facilitate the apoptotic signaling in
neuroblastoma
Seeking an explanation for BAP-mediated apoptosis and
the reduced expression of cell survival factors in neuro-
blastoma cells, we performed a LC–MS/MS analysis.
Immunoprecipitation (IP) of FLAG-tagged BAP1 in SK-
N-SH followed by LC–MS/MS analysis identiﬁed
different isoforms of 14-3-3 proteins including 14-3-3-σ,
-ζ, -ε, and -β (Fig. 3a, Supplementary Fig. 11, and Sup-
plementary Table 1). Figure 3a shows the LC–MS/MS
analysis and one example of a tandem mass spectrum that
unambiguously identiﬁes the sequence 191–224 of 14-3-
3-σ. Further, for the protein 14-3-3-σ, 23 peptides cor-
responding to 83% of sequence coverage were identiﬁed
(Supplementary Fig. 11 and Supplementary Table 1).
Among the other previously identiﬁed BAP1 interacting
partners (https://string-db.org/), we could conﬁrm bind-
ing to CBX3, IPO4, IPO5, and RBBP7 (Supplementary
Fig. 12). The interaction between BAP1 and 14-3-3 pro-
tein was conﬁrmed by performing the co-IP of FLAG-
Fig. 1 Reduced expression of BAP1 in neuroblastoma cell lines. a Western blot analysis of BAP1 and actin expression in SK-N-Be2c, IMR32, SK-N-
F1, SK-N-SH, and SK-N-RA cells (n= 5). b Fold changes in BAP1 mRNA expression, measured using real-time reverse transcription PCR (qRT-PCR) of
cDNA from SK-N-Be2c, IMR32, SK-N-F1, SK-N-SH, and SK-N-RA cells. The IMR32 mRNA expression is set to 1 (mean ± s.e.m., n= 3, ***P < 0.001). c
Phase-contrast microscopy and confocal images of SK-N-BE2c cells transiently transfected with empty plasmid (Ctrl.) or BAP1 expression plasmid for
72 h. The neurite outgrowth in BAP1 expressing cells is shown by staining with anti-α-tubulin antibody and DAPI stain nuclei (blue) (n= 5). d The
morphological effects of the overexpression of BAP1 or empty plasmid (Ctrl.) in SK-N-BE2c cells by counting the number of cells with cell processes
longer than the length of two cell bodies (mean ± s.e.m., n= 3, ***P < 0.001). e The cell proliferation was determined by cell counting after 24–96 h
using lentivirus infected SK-N-SH (upper panel) and SK-N-RA (lower panel) with GFP (Ctrl.) or BAP1. The experiment was performed in triplicate. Data
are presented as mean ± s.e.m. (n= 4, *P < 0.05). f, g Representative histogram plots (n= 3) displaying changes in cell cycle distribution as a result of
BAP1 overexpression assessed using propidium iodide (PI) staining in SK-N-Be2c cells unsynchronized (f) or synchronized by nocodazole (100 ng/ml)
for 18 h (g). The synchronized cells were released after 48 h and cell cycle proﬁle experiment was performed using BD FACS Verse™. The histogram
plot and the percentage of cells in sub-G1, G1, S, and G2/M were determined using FlowJo v10 software (TreeStar)
Sime et al. Cell Death and Disease  (2018) 9:458 Page 7 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 2 (See legend on next page.)
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tagged BAP1 and pull-down of endogenous 14-3-3 in
neuroblastoma cells (Fig. 3b). The reciprocal IP using 14-
3-3 antibodies also indicated the formation of the com-
plex between BAP1 and 14-3-3 (Fig. 3c). In addition,
ﬂuorescence resonance energy transfer (FRET) assay
demonstrated a direct interaction between BAP1 and 14-
3-3 (Fig. 3d). GST pull-down experiments demonstrated
that BAP1 could associate with all of the 14-3-3 isoforms
in the cell (Fig. 3e). To deﬁne which domain(s) in BAP1 is
required for interaction with 14-3-3-σ, a series of FLAG-
tagged BAP1 deletion mutants (Fig. 3f) were transiently
transfected together with full-length GST-tagged 14-3-3-
σ into HEK293T cells. GST pull-down assays demon-
strated that the deletion mutants containing the BAP1
domains NORS (non-regular secondary structure), and
ULD (ubiquitin-like domain) interact with 14-3-3-σ
(Fig. 3g and Supplementary Fig. 13A). Furthermore,
GST pull-down assays using 14-3-3-σ deletion mutants
(Fig. 3g), showed an interaction between truncation 163-
248 and full-length BAP1 (Fig. 3h and Supplementary
Fig. 13B). We could also conﬁrm that the short fragment
of BAP1-ULD domain and 14-3-3-alpha helices 7-9
regions facilitate interaction between these two proteins
(Fig. 3i), while the interaction between BAP1 and 14-3-3-
σ inactive mutants were reduced compared to the full-
length 14-3-3-σ (Fig. 3j). We could not observe any dif-
ferences in the total levels of 14-3-3 protein expression in
the cells expressing low levels of BAP1 (Fig. 4a) or
cells that have been transfected with full-length BAP1 or
BAP1-C91A (Fig. 4b). To analyze, whether 14-3-3 can
undergo ubiquitination, the overall levels of ubiquitin-
associated 14-3-3 in BAP1- or empty plasmid-transfected
neuroblastoma was investigated. We could not
observe any differences in the levels of 14-3-3 ubiquiti-
nation in the absence or presence of BAP1 expression
(Supplementary Fig. 14). The overexpression of BAP1-
C91A did not show any differences in the 14-3-3 ubi-
quitination compared to the BAP1 expressing cells
(Fig. 4b and Supplementary Fig. 14). Next, we tested the
hypothesis that the BAP1 interaction with 14-3-3 releases
the binding between 14-3-3 and Bax, which further
facilitates cell death. Indeed, an IP experiment,
showed that the interaction between 14-3-3 and Bax is
abrogated in the presence but not in the absence of
BAP1 (Fig. 4c). The reciprocal IP using Bax antibodies
conﬁrmed the release of the interaction between
Bax and 14-3-3 in the presence of BAP1 (Fig. 4d). The
treatment of neuroblastoma cells with BV02, which is an
inhibitor of 14-3-3 and prevents the scaffolding function
of 14-3-3 promoted cell death in a concentration-
dependent manner (Fig. 4e). The percentage of apopto-
tic cells treated with 20 µM BV02 was similar to the
cells transfected with BAP1 (Fig. 4f). In addition, siRNA
oligos protected neuroblastoma cells against 14-3-3-ζ
(see ﬁgure on previous page)
Fig. 2 BAP1 induces cell death and downregulates expression of survival genes. a SK-N-SH cells were transiently transfected with control or
BAP1 expression plasmid for 48 h and analyzed for apoptosis by ﬂow cytometry following PE and 7-AAD staining. Quadrants are as follows: lower left:
viable cells; lower right: early apoptotic; upper right: late apoptotic/necrotic. The numbers in quadrants represent the percentage of the viable cells
(lower left), early apoptotic (lower right), and late apoptotic/necrotic (upper right). The table (right panel) shows the distribution of viable cells, early
apoptotic and late apoptotic/necrotic from three independent experiments. b SK-N-RA or SK-N-SH cells were transfected with mock or FLAG-BAP1
for 24 h. Cells were ﬁxed and treated for DNA fragmentation assay. Data represent the percentage of cells with fragmented DNA. Data are presented
as mean ± s.e.m. (n= 3, *P < 0.05). c Cell death visualized by propidium iodide (PI) staining in SK-N-RA and SK-N-SH cells infected with control (GFP) or
FLAG-tagged full-length BAP1. Results are mean ± s.e.m. of percentage cells (*P < 0.05) with PI staining from three independent experiments
counting 200 cells in triplicate. d Extracts from synchronized and released SK-N-RA cells transfected with FLAG-tagged full-length BAP1 were
examined by western blotting (WB) in relation to post-release time points with an anti-PARP and anti-laminB. Arrowheads indicate FL-PARP: full-
length PARP and CL-PARP: cleaved PARP. (n= 3). e Effect of BAP1 overexpression in altering mitochondrial membrane potential in SK-N-Be2c cells
was measured by ﬂow cytometry following JC-1 staining. Cells without JC-1 staining were used to demarcate the gates prior to measure the ratio of
red (mitochondria with a non-depolarized ΔΨ) and green (depolarized ΔΨ) ﬂuorescence emissions after JC-1 staining (5 μM). Mitochondrial
membrane potential was shown to be altered in BAP1-overexpressing cells alone (35.9%) or following arsenic treatment (6 μM, 47.4%) (n= 3). f SK-N-
BE2c cells were non-transfected (0 μg/μl) or transiently transfected with different concentration of full-length FLAG-tagged BAP1 expression plasmid
(0.5 μg/μl, 1.5 μg/μl, 3.5 μg/μl, and 7.0 μg/μl) for 48 h and transfected with siRNA oligos against BAP1 for another 48 h as indicated in the ﬁgure.
Results are mean ± s.e.m. of percentage cells (*P < 0.05) with PI staining from three independent experiments counting 200 cells in triplicate. g SK-N-
SH cells were transiently transfected with full-length Flag-tagged BAP1 expression plasmid (7.0 μg/μl) for 48 h and transfected with siRNA oligos
against BAP1 for 48 h. The cells were treated with Annexin V-PE and 7-AAD before ﬂow cytometry analysis. Representative experiment shows
numbers in quadrants represent the percentage of the viable cells (lower left), early apoptotic (lower right), and late apoptotic/necrotic (upper right)
(n= 3). h SK-N-SH cells were transiently transfected with full-length FLAG-tagged BAP1 expression plasmid (7.0 μg/μl) for 48 h and transfected with
siRNA oligo against BAP1 for 48 h. Cells were ﬁxed and treated with DAPI. Representative experiment shows alterations in DNA content and cell cycle
proﬁles using Nucleocounter NC-3000 (n= 3). i The Human Apoptosis RT² Proﬁler PCR Array revealed up- and downregulated genes involved in
programmed cell death in SK-N-RA cells transiently transfected with full-length FLAG-tagged BAP1 compared to control (empty vector). The level of
relative expression for each particular gene in the two samples are plotted in log–log scatter plot after normalization against ﬁve housekeeping
genes. The line in the middle indicates relative fold changes. Red color indicates upregulated and green color indicates downregulated genes (n= 2).
j Western blot analysis of full-length BAP1 expression in SK-N-RA cells analyzed by blotting with an anti-Bcl-2, anti-BAP1, or anti-actin antibody (n= 3)
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Fig. 3 Identiﬁcation of 14-3-3 protein as a novel binding partner to BAP1. a Representative LC–MS/MS chromatogram of in-gel digested sample
depicted in red, an example of the peptide from 1433S protein eluted at 70.8 min. The Orbitrap mass spectra of the quadruply charged 1433S
peptide sequence 191–224 (m/z 836.9045) enabled mass determination of the peptide (isotopic distribution depicted in gray). The assigned
fragmentation pattern of sequence 191–224 peptide is given in black. b, c SK-N-RA cells were transfected with FLAG-tagged full-length BAP1 or Flag-
empty vector (Ctrl) and lysates were immunoprecipitated with antibodies against FLAG (b) or 14-3-3 (c) and probed with FLAG to detect BAP1 or 14-
3-3 as indicated in the ﬁgure (n= 3). d TR-FRET assay using FRET buffer (Ctrl), puriﬁed control GST (negative control), GST-14-3-3 protein, and His-
BAP1 mixed in FRET buffer, followed by addition of anti-GST-Terbium and anti-His-D2 antibodies. The FRET signals were detected using an Envision
spectrophotometer. The data were presented as the ratio of counts at 665/counts at 620 nm × 104 with standard deviation calculated from triplicate
samples (mean ± s.e.m., n= 3, *P < 0.05). e GST pull-down experiment using co-transfection of cells with GST-tagged 14-3-3 isoforms and full-length
BAP1 followed by addition of GST-conjugated sepharose beads. The eluted whole-cell lysate was subjected to SDS-PAGE and analyzed by western
blot using anti- FLAG, anti-GST, or anti-actin antibodies (n= 3). f Schematic representation of 14-3-3σ (9 alpha-helix) and BAP1 domains consisting of
UCH (ubiquitin C-terminal hydrolases), NORS (non-regular secondary structure), ULD (ubiquitin like domain), and NLS (nuclear localization sequence).
Residues numbers refer to amino acid positions. g GST pull-down experiment using co-transfection of cells with GST-tagged 14-3-3σ and FLAG-
tagged full-length or deletion mutants of BAP1 followed by addition of GST-conjugated sepharose beads. The eluted whole-cell lysate was subjected
to SDS-PAGE and analyzed by western blot using anti-FLAG, anti-GST, or anti-actin antibodies (n= 3). h GST pull-down experiment using co-
transfection of cells with GST-tagged full-length or deletion mutant of 14-3-3σ and FLAG-tagged full-length BAP1 followed by addition of GST-
conjugated sepharose beads. The eluted whole-cell lysate was subjected to SDS-PAGE and analyzed by western blot using anti-FLAG, anti-GST, or
anti-actin antibodies (n= 3). i GST pull-down experiment using co-transfection of cells with GST-tagged full-length or deletion mutant of 14-3-3σ and
full-length or FLAG-tagged deletion mutant of BAP1 (aa 635–694) followed by addition of GST-conjugated sepharose beads. The eluted whole-cell
lysate was subjected to SDS-PAGE and analyzed by western blot using anti-FLAG, anti-GST, or anti-actin antibodies (n= 3). j GST pull-down
experiment using co-transfection of cells with GST-tagged 14-3-3σ, 14-3-3σ mutant (σ-K49E), and full-length BAP1 followed by addition of GST-
conjugated sepharose beads. The eluted whole-cell lysate was subjected to SDS-PAGE and analyzed by western blot using anti-FLAG, anti-GST, or
anti-actin antibodies (n= 3)
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facilitated cell death (Fig. 4g, h). These results suggest that
BAP1 interaction with 14-3-3 prevents cell survival sig-
naling, which is essential for growth of the neuroblastoma
cells (Fig. 4i).
Next, we subcutaneously implanted 5.0 × 106 of control
and BAP1 expressing neuroblastoma cells in nude mice
and followed the growth of the tumor for 25 days. It was
evident that the weight and mass of BAP1 stably expres-
sing tumors were markedly reduced compared to control
mice (Fig. 5a–d), conﬁrming the effects of BAP1 on
neuroblastoma cell growth in vivo. As expected, BAP1
expression was elevated in tumor cells infected with BAP1
compared with control cells using IHC and western
blotting (Fig. 5e, g). In addition, the Bcl-2 expression in
BAP1 tumor cells isolated from mice were reduced
compared to the control cells in line with the elevated
number of cleaved caspase-3 cells observed in BAP1
expressing tumor cells (Fig. 5e–g). Investigating the levels
of cytochrome C in the tumor tissues isolated from ani-
mals revealed the downregulation of this protein in the
Fig. 4 BAP1 binding to 14-3-3 releases Bax for inducing apoptosis. a Western blot analysis of 14-3-3 and actin expression in SK-N-Be2c, SK-N-SH,
and SK-N-RA cells (n= 5). b Western blot analysis of 14-3-3 and actin expression in SK-N-Be2c transiently transfected with empty vector, full-length
BAP1, or catalytically inactive mutant of BAP1 (BAP1-C91A) (n= 4). c, d SK-N-RA cells were transfected with FLAG-tagged full-length BAP1 or FLAG-
empty vector. The lysates were immunoprecipitated with antibodies against 14-3-3 (c) or Bax (d) and probed with antibodies against 14-3-3 or Bax as
indicated in the ﬁgure (n= 3). e Titration of BV02 in SK-N-RA cells for 24 h using three different concentrations (5, 20, and 100 μM). The percentage of
apoptotic cells is presented as four independent experiments in triplicate (*p < 0.05). f SK-N-RA cells were transfected with control expression plasmid
(white), transfected with full-length BAP1 expression plasmid (blue), or transfected with control expression plasmid and treated with 20 μM BV02 for
24 h (green). The percentage of apoptotic cells is presented as three independent experiments in triplicate (*p < 0.05). g Relative 14-3-3-ζ mRNA
expression levels as fold changes measured using real-time reverse transcription PCR (qRT-PCR) of cDNA from transfected SK-N-RA cells with siRNA
against 14-3-3-ζ or siRNA-GFP-Ctrl. The data are represented as three independent experiments (*p < 0.05). h The percentage of apoptotic cells in SK-
N-RA cells transfected with siRNA against 14-3-3-ζ or siRNA-GFP-Ctrl in four independent experiments (*p < 0.05). i Model of BAP1-induced regulation
of cell survival and cell death in neuroblastoma cells. BAP1 induces cell death via an interaction with 14-3-3 protein. The association between BAP1
and 14-3-3 releases the apoptotic inducer protein Bax from 14-3-3 and promotes cell death through the intrinsic (mitochondria) apoptosis pathway
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control cells compared with BAP1 expressing tumors
(Fig. 5g).
BAP1 expression and copy number alterations in
neuroblastoma patients and cell lines
The analysis of gene expression array data of 102 neu-
roblastomas (Stage 4 and non-MYCN ampliﬁed) showed
that there is a trend toward the association between high
BAP1 and Bax expression and better relapse-free survival
of the patients (Fig. 6a, b). Furthermore, we evaluated
BAP1 gene expression levels in two data sets of NB
patients provided with COG risk category annotation. It
was found lower levels of BAP1 expression in high-
risk individuals of both data sets compared to low-risk
patients (Intermediate risk patients were excluded,
Fig. 6c). Copy number alterations proﬁles for SK-
N-SH, SK-N-F1, IMR32, SK-N-DZ, SK-N-Be2, and SK-
N-Be2c cell lines were obtained from recently
published genotyping proﬁles33,34 by using Illumina
HumanOmniExpress-24 v1.0 BeadChip (GPL21168).
deposited at GEO database with accession numbers
GSM2394365, GSM2394387, GSM2394364,
GSM2394375, GSM2394372, and GSM2394383, respec-
tively (GEO series: GSE89968). We used available log
ratios and B allele frequencies to call copy number
alterations with the R-Bioconductor package “copy
number”35. The program was used to detect and remove
outliers, impute missing values and to perform allele
speciﬁc segmentation of SNP-array data. Log ratio
thresholds for calling segments as gains or losses were set
at 0.2 and −0.16, respectively. Figure 6d shows the whole-
genome copy number alteration proﬁle for the afore-
mentioned cell lines. This analysis allowed us to conﬁrm
the well-known genomic features of the reported cell
lines, including the loss-of-chromosome 1p in IMR32 and
the ampliﬁcation of MYCN in SK-N-DZ and IMR32.
Figure 6e depicts a zoom-in of the copy number altera-
tions proﬁle for chromosome 3. We found that the cell
line SK-N-Be2 had a large deletion (17,639,767 base pairs
[bp], represented by 3870 probes on the chip) at
Fig. 5 BAP1 reduces tumor growth in vivo. a–d Nude mice were randomly divided into 2 groups of 10 mice after each being injected with 5 × 106
SK-N-BE2c cells stably expressing empty expression vector (Ctrl) or FLAG-tagged full-length BAP1. Tumor sizes were measured at the indicated time
points. Tumor volumes were estimated based on the length and width of the tumors: [mm3]= (length [mm]) × (width [mm])2 × 0.5. (V= L ×W2 ×
0.5). The number of animals with certain tumor volume is presented in d. The mean tumor volume for each treatment group was graphed plus/
minus standard errors (*p < 0.05). e Immunohistochemistry analysis of tumor biopsies isolated from control (Ctrl) or BAP1 expressing neuroblastoma
cells using H&E or antibodies against BAP1 (1:500), Bcl-2 (1:1000), and cleaved caspase-3 (Asp175, 1:500). Arrowheads indicate cleaved caspase-3
positive cells. f Quantiﬁcation of the number of cleaved caspase-3 (Asp175) positive cells in percentage visualized in the sections isolated from
control or BAP1 expressing neuroblastoma cells (p < 0.05*). g Relative BAP1 expression and its effect on the expression of Bcl-2 and cytochrome C
was determined by western blot from tumor tissue. Actin was used as the internal controls for western blotting
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chromosome 3p including BAP1 (Fig. 6f, upper panel) and
shared with its descendant cell line SK-N-Be2c shown in
Fig. 6f (middle panel). Further, we detected a homozygous
deletion (Fig. 6f, lower panel), including chromosome
3p21.1 of SK-N-DZ cell line as reported in Cancer Cell
Line Encyclopedia data36 available at cBioportal website
(http://www.cbioportal.org). Here we used the Affymetrix
Genome-Wide SNP 6.0 Array to estimate genomic copy
number proﬁles and Affymetrix HG U133 Plus 2.0 plat-
form to measure gene expression levels. Of the
1019 samples, we selected those for which mutation
data, copy number proﬁles, and gene expression data
were available (thus, restricting the analysis to 877
samples). Subjects that showed an alteration of BAP1
locus or its expression level numbered 148/877 or 17%.
Copy number alteration proﬁle for the SK-N-SH
cell line treated with retinoic acid (SK-N-SH-RA) was
available at the GEO repository (GSM999325, series:
GSE40698) and at the UCSC Genome Browser as part of
HAIB Genotype track set from ENCODE/HudsonAlpha
Fig. 6 BAP1 expression and copy number alterations in neuroblastoma patients and cell lines. a, b BAP1 (P= 0.14) and Bax (P= 0.229)
expression is associated with good outcome. Kaplan–Meier analysis using published array data from 102 patients with stage 4, non-MYCN ampliﬁed
neuroblastoma. c Box plots showing the Log2 transformed expression proﬁles of BAP1 NB cohorts divided by COG Risk category (Intermediate risk
patients were excluded). Left panel: BAP1 expression in the TARGET-NBL data set. Right panel: BAP1 expression in GSE73517 data. Gene expression
data were downloaded from R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) and plotted using the R environment. Statistical
signiﬁcance was assessed by ANOVA test. d Whole-genome aberration plot of the six cell lines from the GEO series GSE89968 (in blue) are reported
chromosomal losses and (in red) chromosomal gains, as well as the diploid regions in white. The black box highlights chromosome 3. e Zoomed-in
view of chromosome 3 indicating altered regions. f Copy number alteration proﬁle for chromosome 3 of SK-N-Be2c, SK-N-Be2c, and SK-N-DZ. LogR:
log ratio values, BAF: B allele frequencies. The plots in d, e show deletion of BAP1 locus
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(http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=
wgEncodeHaibGenotype). No genomic alterations were
found for the SK-N-SH cell line and for the derived SK-N-
SH-RA cell line in chromosome 3p.
Discussion
BAP1 is a tumor suppressor gene that functions as a
deubiquitinating enzyme. The human BAP1 locus is
located on chromosome 3p21.3. This region is commonly
deleted or rearranged in many types of human cancer,
such as lung, breast, melanoma, and renal cell carci-
noma13,37. The role of BAP1 in neuroblastoma is
unknown. In this study, we found that BAP1 was down-
regulated both at the RNA and protein level in a subset of
neuroblastoma cell lines. Large scale hemizygous loss-of-
chromosome 3p is a common event in neuroblastoma,
and it is associated with tumors from older children38,39.
Recurrent deletions have been found at locus 3p21-p22 in
neuroblastoma and other common tumors, including
breast and lung cancer, indicating that the same tumor
suppressors are involved in tumorigenesis in these dif-
ferent tumors40. Deletion of chromosome 3p was also
non-randomly associated with deletion of chromosome
11q in neuroblastoma41. Furthermore, loss-of-
chromosomal material in chromosome arms 3p was dis-
covered as a new high-risk subgroup of neuroblastoma
stage 4 disease38. To investigate the role of BAP1, we
overexpressed full-length BAP1 or BAP1-C91A in differ-
ent neuroblastoma cell lines. The restoration of full-
length BAP1 but not BAP1-C91A expression in these cells
inhibited cell proliferation and promoted cell death sug-
gesting that deubiquitin activity of BAP1 is necessary for
the observed phenotype. More precisely, BAP1 increased
the subG1 subpopulation of cells. Previous studies showed
that BAP1 is known as a key regulator of cell cycle pro-
gression through G1/S transition22,25 and that BAP1
depletion in double-thymidine arrested HeLa cells leads
to delayed entry into the S phase, potentially as a result of
an inability of cells to respond to DNA damage during this
phase14. Furthermore, in NCI-H226, which are BAP1-null
cells, overexpression of wild-type BAP1 promotes G1
phase exit and subsequently speeds the transition to S
phase15.
Two different strategies were applied to analyze the
mechanism of BAP1 inducing cell death in neuro-
blastoma. First, we investigated the expression of apop-
tosis and survival target genes in cells expressing BAP1
compared to control cells. Second, we performed
LC–MS/MS analysis to identify binding partners for
BAP1 that could propagate cell death signaling. Gene
expression proﬁling identiﬁed multiple genes in the cell
survival pathway that were downregulated in BAP1
expressing cells. One of these target genes was the
Bcl-2 protein. Independent of the neuroblastoma cell line
tested, BAP1 expression promoted the downregulation of
Bcl-2. The Bcl-2 family consists of anti-apoptotic, pro-
apoptotic multi-domain, and pro-apoptotic BH3-only
proteins. Bcl-2 and Bcl-XL are well known anti-apoptotic
family members; whereas, Bax and Bak are among the
pro-apoptotic multi-domain proteins42. In neuro-
blastoma, a large subset of patients harbor elevated levels
of Bcl-2 compared to normal tissues11 and the silencing or
inhibition of Bcl-2 in neuroblastoma cell lines results in
apoptosis11. Further, siRNA targeting of Bcl-2 in neuro-
blastoma causes a high level of cell apoptosis and a sig-
niﬁcant suppression of tumor growth43. Previous studies
also demonstrated that high-risk neuroblastoma cell lines
derived from human tumors with the poorest prognosis
are dependent on Bcl-2 for survival10. In addition, ele-
vated Bcl-2 family protein expression was correlated to
chemotherapy resistance12. In correlation with these
previous ﬁndings, our data suggest that the expression of
BAP1 leads to reduced expression of pro-survival factors
such as Bcl-2, which in turn reduces the survival potential
of these cells. Indeed, in vivo xenograft studies using
BAP1 expressing cells showed reduced tumor growth
compared to the control cells. Further, the tumors iso-
lated from BAP1 expressing cells harbored an elevated
number of cleaved caspase-3 and increased the expression
of cytochrome C. In correlation to this result, the analyses
of neuroblastoma patient tumor materials revealed that
the high BAP1 and Bax mRNA expression shows a trend
toward a better clinical outcome. Recent whole-genome
sequencing studies of neuroblatoma did not ﬁnd genomic
aberrations of the BAP1 locus44. However, 3p deletion in
neuroblastoma has been reported in previous studies45.
Therefore, additional studies including treatment proto-
col data, protein expression, and larger sample sizes are
necessary to investigate the potential role of the genomic
aberrations of the BAP1 locus in driving the carcinogen-
esis of neuroblatoma.
LC–MS/MS analysis identiﬁed 14-3-3 proteins as novel
binding partners for BAP1. The intracellular localization
and scaffolding potential of 14-3-3 through direct inter-
action with their target protein is vital for regulating
intracellular signaling pathways46. The 14-3-3 proteins
can prevent cell apoptosis via direct interaction with Bcl-2
family members including Bad and Bax. In contrast,
apoptotic stimulation, releases Bad or Bax from 14-3-3,
and induces cytochrome C-mediated cell death47. The
isoform speciﬁcity in our mass spectrometry analysis
identiﬁed 14-3-3-σ, -ζ, -ε, and -β. Pull-down experiments
and confocal microscopy demonstrated direct interaction
and co-localization in the nucleus. Testing the total levels
of 14-3-3 in the neuroblastoma cells, we found no changes
in the cell lines harboring reduced levels of BAP1. In
addition, we found no changes in the levels of 14-3-3
ubiquitination in the absence or presence of full-length
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BAP1 and BAP1-C91A. Instead, we found that BAP1
interaction with 14-3-3 releases the interaction between
14-3-3 and Bax, which in turn promotes cell death
(Fig. 4i). The siRNA targeting of 14-3-3-ζ, or treating the
cells with BV02, an inhibitor of 14-3-3 scaffolding protein
docking sites, mimicked the effect of BAP1-mediated
apoptosis. In general, the elevated levels of 14-3-3-ζ have
been shown to be associated with different types of can-
cer, including lung, breast, prostate, myeloma, glioma,
esophageal, head and neck, oral, pancreatic, ovarian, and
skin. In most of these studies, the expression of 14-3-3-ζ
was correlated with poor prognosis and chemoresis-
tance46,48. In neuroblastoma BH3 peptides containing the
domains of the pro-apoptotic BH3-only proteins Bid and
Bad, -induced apoptosis and demonstrated antitumor
efﬁcacy in an in vivo model49.
In summary, our present ﬁndings suggest that the
reduced expression of BAP1 triggers neuroblastoma cells
to survive and grow faster compared to the BAP1
expressing cells. The restoration of BAP1 expression in
neuroblastoma cells facilitated cell death mediated by
direct interaction with 14-3-3 and releasing Bax from this
complex. Our ﬁndings might have important implications
for BAP1 to play a key role in the regulation of cell death
in cancer cells, and the expression of BAP1 could have
prognostic implications in predicting a good prognosis in
cancer patients.
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